Primary central nervous system lymphoma

Current Opinion in Neurology

Volumn 12, Issue 6, 1999, Pages 687-691

  DeAngelis, Lisa M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; METHOTREXATE; PREDNISONE; PROCARBAZINE; SAQUINAVIR; THIOTEPA; VINCRISTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; BLOOD BRAIN BARRIER; BRAIN BIOPSY; BRAIN LYMPHOMA; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG PENETRATION; EPSTEIN BARR VIRUS; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOENCEPHALOPATHY; MALE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE; REVIEW;

CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA;

EID: 0033384367     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199912000-00005     Document Type: Review

References (36)

1. Schaumburg HH, Plank CR, Adams RD. The reticulum cell sarcoma microglioma group of brain tumours. Brain 1972; 95:199-212.
2. Eby NL, Grufferman S, Flanelly CM, Schol SC, Vogel FS, Burger PC. Increasing incidence of primary brain lymphoma in the US. Cancer 1998; 62:2461-2465.
3. DeAngelis LM. Current management of primary central nervous system lymphoma. Oncology 1995; 9:63-71.
4. Forsyth PA, DeAngelis LM. Biology and management of AIDS-associated primary CNS lymphomas. Hematol/Oncol Clin North Am 1996; 10:1125-1134.
5. Lutz J-M, Coleman MP. Trends in primary cerebral lymphoma. Br J Cancer 1994; 70:716-718.
6. Bashir RM, Harris NL, Hochberg FH, Singer RM. Detection of Epstein-Barr virus in CNS lymphoma by in-situ hybridization. Neurology 1989; 39:813-817.
7. Balmaceda C, Gaynor JJ, Sun M, Gluck JT, DeAngelis LM. Leptomeningeal tumor in primary central nervous system lymphoma. Ann Neurol 1995; 38:202-206.
8. Ciricillo SF, Rosenblum ML. Use of CT and MR imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients. J Neurosurg 1990; 73:1720-1728.
9. Singh A, Strobos RJ, Singh BM, Rothballer AB, Reddy V, Puljic S, et al. Steroid-induced remissions in CNS lymphoma. Neurology 1982; 32:1267-1271.
10. Van den Bent MJ, Vanneste JAL, Ansink BJJ. Prolonged remission of primary central nervous system lymphoma after discontinuation of steroid therapy. J Neuro-Oncol 1992; 13:257-259.
11. 201 thallium single photon emission tomography. AIDS 1997; 11:1522-1523.
12. Lorberboym M, Wallach F, Estok L, Mosesson RE, Sacher M, Kim CK, et al. Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant in AIDS patients. J Nucl Med 1998; 39:1366-1369.
13. Brink NS, Sharvell Y, Howard MR, Fox JD, Harrison MJG, Miller RF. Detection of Epstein-Barr virus and Kaposi's sarcoma-associated herpes virus DNA in CSF from persons infected with HIV who had neurological disease. J Neurol Neurosurg Psychiatry 1998; 65:191-195.
14. Matthews C, Barba D, Fullerton SC. Early biopsy versus empiric treatment with delayed biopsy of non-responders in suspected HIV-associated cerebral toxoplasmosis: a decision analysis. AIDS 1995; 9:1243-1250.
15. DeAngelis LM, Yahalom J, Heinemann M-H, Cirrincione C, Thaler HT, Krol G. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 1990; 40:80-86.
16. Rampen FHJ, van Andel JG, Sizoo W, van Unnik JAM. Radiation therapy in non-Hodgkin lymphomas of the CNS. Eur J Cancer 1980; 16:177-184.
17. Nelson DF, Martz KL, Bonner H, Nelson JS, Newal J, Kerman HD, et al. Non-Hodgkin's lymphomas of the brain: can high dose, large volume radiation improve survival? Report on a prospective trial by the RTOG. Int J Radiat Oncol Biol Phys 1992; 23:9-17.
18. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992; 10:635-643.
19. Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, et ai Pre-irradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 1996; 14:556-564.
20. O'Neill BP, O'Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys 1995; 33:663-673.
21. Brada M, Dearnaley D, Horwich A, Bloom HJG. Management of primary cerebral lymphoma with initial chemotherapy: preliminary results and comparison with patients treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 1990; 18:787.
22. Abrey LE, DeAngelis LM, Yahalom J. Long term survival in primary CNS lymphoma. J Clin Oncol 1998; 16:859-863. Combined modality therapy markedly improves the survival of immunocompetent patients with PCNSL.
23. Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998; 16:864-870. High-dose methotrexate is the most important treatment factor in achieving an improved outcome.
24. Pitman SW, Frei E III. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. Cancer Treat Rep 1997; 61:695-701.
25. 2 in children with acute lymphoblastic leukemia. Cancer 1987; 60:5-13.
26. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975; 293:161-166.
27. Reni M, Ferreri AJM, Garancini MP, et al. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 1997; 8:227-234.
28. Freilich RJ, Delattre J-Y, Monjour A, DeAngelis LM. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 1996; 46:435-439.
29. Sandor V, Stark-Vanes V, Pearson D, Nussenblat R, Whitcup SM, Brouwers P, et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 1998; 16:3000-3006. Chemotherapy alone can achieve remissions in PCNSL.
30. Dahlborg SA, Henner WD, Crossen JR, Taableman M, Petrillo A, Braziel R, et al. Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhances chemotherapy delivery without cognitive loss and without radiotherapy. Can J Sci Am 1996; 2:166-174.
31. Bleyer WA. Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 1981; 65:89-98.
32. Delattre JY, Shapiro WR, Posner JB. Acute effects of low dose cranial irradiation on regional capillary permeability in experimental brain tumors. J Neurol Sci 1988; 90:147-153.
33. Ling SM, Roach A, Larson DA, Wara WM. Radiotherapy of primary CNS lymphoma in patients with and without HIV. Cancer 1994; 73:2570-2582.
34. Forsyth PA, Yahalom J, DeAngelis LM. Combined modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology 1994; 44:1473-1478.
35. Jacomet C, Girard P-M, Lebrette M-G, Farese VL, Monfort L, Rozenbaum W. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS 1997; 11:1725-1730.
36. McGowan JP, Shah S. Long term remission of AIDS-related primary central nervous system lymphoma associated with highly active antiretroviral therapy. AIDS 1998; 12:952-953.